{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinitis+Pigmentosa&page=2",
    "query": {
      "condition": "Retinitis Pigmentosa",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinitis+Pigmentosa&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:48:48.729Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00407602",
      "title": "Argus® II Retinal Stimulation System Feasibility Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Implant of Argus II Retinal Prosthesis",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Second Sight Medical Products",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2006-09",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-01-20",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407602"
    },
    {
      "nct_id": "NCT03597399",
      "title": "A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy"
      ],
      "interventions": [
        {
          "name": "AAV2-hRPE65v2,voretigene neparvovec-rzyl",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Months and older"
      },
      "enrollment_count": 87,
      "start_date": "2019-01-10",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Miami, Florida • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03597399"
    },
    {
      "nct_id": "NCT05176717",
      "title": "Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Usher Syndrome Type 2",
        "Deaf Blind",
        "Retinal Disease",
        "Eye Diseases",
        "Eye Diseases, Hereditary",
        "Eye Disorders Congenital",
        "Vision Disorders"
      ],
      "interventions": [
        {
          "name": "QR-421a",
          "type": "DRUG"
        },
        {
          "name": "Sham-procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-12-15",
      "completion_date": "2022-08-02",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05176717"
    },
    {
      "nct_id": "NCT02435940",
      "title": "Inherited Retinal Degenerative Disease Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Eye Diseases Hereditary",
        "Retinal Disease",
        "Achromatopsia",
        "Bardet-Biedl Syndrome",
        "Bassen-Kornzweig Syndrome",
        "Batten Disease",
        "Best Disease",
        "Choroidal Dystrophy",
        "Choroideremia",
        "Cone Dystrophy",
        "Cone-Rod Dystrophy",
        "Congenital Stationary Night Blindness",
        "Enhanced S-Cone Syndrome",
        "Fundus Albipunctatus",
        "Goldmann-Favre Syndrome",
        "Gyrate Atrophy",
        "Juvenile Macular Degeneration",
        "Kearns-Sayre Syndrome",
        "Leber Congenital Amaurosis",
        "Refsum Syndrome",
        "Retinitis Pigmentosa",
        "Retinitis Punctata Albescens",
        "Retinoschisis",
        "Rod-Cone Dystrophy",
        "Rod Dystrophy",
        "Rod Monochromacy",
        "Stargardt Disease",
        "Usher Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Foundation Fighting Blindness",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20000,
      "start_date": "2014-06",
      "completion_date": "2037-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 1,
      "location_summary": "Columbia, Maryland",
      "locations": [
        {
          "city": "Columbia",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02435940"
    },
    {
      "nct_id": "NCT04966741",
      "title": "Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bardet-Biedl Syndrome",
        "POMC Deficiency Obesity",
        "PCSK1 Deficiency Obesity",
        "LEPR Deficiency Obesity"
      ],
      "interventions": [
        {
          "name": "Setmelanotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rhythm Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "2 Years to 5 Years"
      },
      "enrollment_count": 12,
      "start_date": "2022-03-08",
      "completion_date": "2024-11-08",
      "has_results": true,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • New York, New York • Marshfield, Wisconsin",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04966741"
    },
    {
      "nct_id": "NCT06092346",
      "title": "A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "AMPD3, OMIM*102772, AMP Deaminase Deficiency",
        "AK1, OMIM *103000, Adenylate Kinase Deficiency",
        "AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency",
        "TPMT, OMIM *187680, Thoipurines, Poor Metabolism of",
        "IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11",
        "APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency",
        "HPRT1, OMIM *308000 Lesch-Nyhan Disease",
        "XDH, OMIM *607633, Xanthinuria Type 1",
        "SLC2A9, OMIM *606142 Hypouricemia",
        "SLC22A12, OMIM *607096 Hypouricemia",
        "PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease",
        "PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity",
        "AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia",
        "ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35",
        "ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency",
        "PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency",
        "ADA2, OMIM *607575,Sneddon Syndrome; VAIHS",
        "CAD, *1140120, Developmental and Epileptic Encephalopathy",
        "UPB1, OMIM *606673, Beta-ureidopropionase Deficiency",
        "DPYS, OMIM *613326, Dihydropyrimidinase Deficiency",
        "DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency",
        "DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis)",
        "UMPS, OMIM *613891, Orotic Aciduria",
        "NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency",
        "UNG, OMIM *191525, Hyper-IgM Syndrome 5",
        "AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2",
        "Purine-Pyrimidine Metabolism",
        "Metabolic Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "1 Month to 100 Years"
      },
      "enrollment_count": 999,
      "start_date": "2023-12-19",
      "completion_date": "2099-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06092346"
    },
    {
      "nct_id": "NCT06565572",
      "title": "Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Posterior Column Ataxia With Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "nL-FLVC-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2023-08-23",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06565572"
    },
    {
      "nct_id": "NCT02548572",
      "title": "Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy Multicenter Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Transcorneal Electrical Stimulation using Okustim device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "22 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-01",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2019-05-01",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548572"
    },
    {
      "nct_id": "NCT02464436",
      "title": "Safety and Tolerability of hRPC in Retinitis Pigmentosa",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "hRPC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ReNeuron Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2015-12",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2023-07-06",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Boston, Massachusetts • Portland, Oregon",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02464436"
    },
    {
      "nct_id": "NCT00004345",
      "title": "Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Usher Syndrome",
        "Retinitis Pigmentosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "1999-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-05-22T06:48:48.729Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004345"
    }
  ]
}